Ifoxetine

Ifoxetine
Systematic (IUPAC) name
(3R,4S)-4-(2,3-dimethylphenoxy)piperidin-3-ol
Clinical data
Legal status
  • Uncontrolled
Routes of
administration
Oral
Identifiers
CAS Number 66208-11-5
ATC code None
PubChem CID 71971
ChemSpider 64977
UNII LHH887104B YesY
ChEMBL CHEMBL2218865
Chemical data
Formula C13H19NO2
Molar mass 221.30 g/mol

Ifoxetine (CGP-15,210-G) is a selective serotonin reuptake inhibitor (SSRI) which was investigated as an antidepressant in the 1980s but was never marketed.[1][2][3] Ifoxetine selectively blocks the reuptake of serotonin in the brain supposedly without affecting it in the periphery.[3] Supporting this claim, ifoxetine was found to be efficacious in clinical trials and was very well tolerated, producing almost no physical side effects or other complaints of significant concern.[3]

References

  1. Burrows GD, McIntyre IM, Judd FK, Norman TR (August 1988). "Clinical effects of serotonin reuptake inhibitors in the treatment of depressive illness". The Journal of Clinical Psychiatry. 49 Suppl: 18–22. PMID 3045107.
  2. Waldmeier PC, Maître L, Baumann PA, et al. (October 1986). "Ifoxetine, a compound with atypical effects on serotonin uptake". European Journal of Pharmacology 130 (1-2): 1–10. doi:10.1016/0014-2999(86)90177-9. PMID 2877890.
  3. 1 2 3 Delini-Stula A, Fischbach R, Gauthier JM, et al. (July 1987). "First clinical experience with ifoxetine, a new 5-HT reuptake blocker with particular emphasis on the side-effect profile of the 5-HT-uptake inhibiting drugs". International Clinical Psychopharmacology 2 (3): 201–15. doi:10.1097/00004850-198707000-00003. PMID 3320185.



This article is issued from Wikipedia - version of the Wednesday, December 16, 2015. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.